Loading clinical trials...

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19 | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

NCT04868890•Ampio Pharmaceuticals. Inc.

View on ClinicalTrials.gov

Summary

This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19

Detailed Description

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the pandemic spread of coronavirus disease 2019 (COVID-19), which has a high rate of infection, has a high rate of hospitalization, has overwhelmed healthcare systems, and can be fatal. Ampion is the low molecular weight filtrate of human serum albumin with the in vitro ability to modulate inflammatory cytokine levels. Ampion has the potential to improve clinical outcomes for COVID-19 patients by reducing inflammatory cytokines correlated with the disease and respiratory complications, such as Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). This study aims to evaluate the effects of Ampion on mortality and clinical outcomes in patients with respiratory distress due to COVID-19.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female, ≥ 18 years old
•2. Diagnosed with COVID-19, as evaluated by laboratory diagnostic test or diagnosis based on radiological clinical findings.
•3. Baseline severity categorization of severe or critical COVID-19 infection per FDA Guidance for developing drugs and biological products for COVID-19 (February 2021):
•1. Severe COVID-19:
•* Symptoms suggestive of severe systemic illness with COVID-19, which could include shortness of breath or respiratory distress
•* Clinical signs indicative of severe systemic illness with COVID-19, such as respiratory rate ≥ 30 per minute, heart rate ≥ 125 per minute, SpO2 ≤ 93% on room air at or PaO2/FiO2 \< 300
•2. Critical COVID-19:
•* Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced cannula at flow rates \> 20 L/min with fraction of oxygen ≥ 0.5) or
•* Non-invasive mechanical or endotracheal mechanical ventilation
•4. Informed consent obtained from the patient or the patient's legal representative.

Exclusion Criteria

•1. As a result of the medical review and screening investigation, the Principal Investigator considers the patient unfit for the study and/or progression to death is imminent and inevitable irrespective of the provision of treatments.
•2. Clinical diagnosis of respiratory failure requiring ECMO and/or therapy is not available due to limitation.
•3. Shock defined by systolic blood pressure \<90 mm Hg, or diastolic blood pressure \<60 mm Hg or requiring vasopressors.
•4. Multi-organ dysfunction/failure.
•5. Patient has severe chronic obstructive or restrictive pulmonary disease (COPD) (as defined by prior pulmonary function tests), chronic renal failure, or significant liver abnormality (e.g., cirrhosis, transplant, etc.).
•6. Patient has chronic conditions requiring chemotherapy or immunosuppressive medication.
•7. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) or ingredients in 5% human albumin (N- acetyltryptophan, sodium caprylate).
•8. Prolonged QT interval.
•9. Patient has known pregnancy or is currently breastfeeding.
•10. Patient planning to become pregnant, or father a child, during the treatment and follow-up period and/or is not willing to remain abstinent or use contraception.
+1 more criteria

Locations (1)

Ampio Pharmaceuticals

Englewood, Colorado, United States

Key Dates

Start Date

June 22, 2021

Primary Completion Date

February 16, 2022

Completion Date

April 13, 2022

Last Updated

December 7, 2022

Enrollment

200

ACTUAL participants

Conditions

Covid19

Interventions

Ampion

BIOLOGICAL

Placebo

OTHER

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy